Fragile X Syndrome Pipeline Summary

DelveInsight’s, “Fragile X Syndrome - Pipeline Insight, 2026” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Fragile X Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Fragile X Syndrome: Understanding

Fragile X Syndrome: Overview

Fragile X syndrome (FXS) is an inherited genetic neurodevelopmental disorder and one of the most common causes of inherited intellectual and developmental disability. It primarily affects cognitive development, learning, communication, behavior and social functioning, with males generally more severely affected than females. Developmental delay, intellectual disability and behavioral difficulties are common, while autism spectrum disorder occurs frequently in affected individuals. Physical features may become more apparent with age and can include a long, narrow face, prominent ears, joint laxity and an enlarged head circumference.

Common signs and symptoms include delayed speech and language development, learning difficulties, impaired attention, anxiety, hyperactivity and social or behavioral problems. Individuals may exhibit poor eye contact, hand-flapping, sensory hypersensitivity, impulsivity or autistic behaviors. Medical manifestations can include hypotonia, seizures, sleep disturbances, recurrent ear infections, strabismus, gastroesophageal reflux, scoliosis and flat feet. In males, intellectual disability is usually more pronounced, whereas females may have normal intelligence or milder cognitive impairment because of variable X-chromosome inactivation.

FXS is primarily caused by a CGG trinucleotide-repeat expansion in the 5? untranslated region of the FMR1 gene on the X chromosome. A full mutation generally contains more than 200 CGG repeats and is usually associated with abnormal methylation and transcriptional silencing of FMR1. This prevents production of fragile X messenger ribonucleoprotein (FMRP), an RNA-binding protein that regulates translation of numerous neuronal proteins. Loss of FMRP disrupts synaptic development and plasticity, alters neuronal signaling and contributes to abnormalities in learning, cognition, behavior and brain development.

Diagnosis is established primarily through molecular genetic testing for CGG-repeat expansion in FMR1, with methylation analysis helping characterize full-mutation alleles; conventional exome or genome sequencing may not detect the repeat expansion reliably. Management is multidisciplinary because there is currently no curative therapy that restores normal FMRP function. Early-intervention programs, individualized education, speech and language therapy, occupational therapy, behavioral interventions and physical therapy are important components of care. Medications may be used to manage associated symptoms such as attention problems, anxiety, aggression, sleep disturbances or seizures, alongside routine management of associated medical conditions and genetic counseling for families.

"Fragile X Syndrome- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fragile X Syndrome pipeline landscape is provided which includes the disease overview and Fragile X Syndrome treatment guidelines. The assessment part of the report embraces, in depth Fragile X Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fragile X Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Fragile X Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Fragile X Syndrome.

Fragile X Syndrome Emerging Drugs Chapters

This segment of the Fragile X Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fragile X Syndrome Emerging Drugs

Zatolmilast: Shionogi

Zatolmilast (BPN14770) is an investigational selective phosphodiesterase-4D (PDE4D) inhibitor being developed by Shionogi for Fragile X syndrome (FXS). By inhibiting PDE4D, it is designed to increase intracellular cAMP signaling, potentially improving neuronal connectivity and supporting cognitive and behavioral function impaired in FXS. Currently, Zatolmilast remains investigational and not FDA-approved, with Shionogi continuing analyses of the Phase III data and the long-term extension study.

CTH120: CONNECTA Therapeutics

CTH120 is an investigational, first-in-class small-molecule neuroplasticity modulator being developed by CONNECTA Therapeutics for Fragile X syndrome (FXS). It targets the tropomyosin receptor kinase B (TrkB/NTRK2) receptor, a key mediator of neuronal development, connectivity and neuroplasticity, with the aim of restoring disrupted neuronal architecture in FXS. Preclinical studies in FXS models demonstrated improvements in cognitive and behavioral deficits and normalization of dendritic spine density and morphology. It is being studies in a Phase IIa randomized, double-blind, placebo-controlled study evaluating the drug in adult males with FXS, primarily assessing safety

and tolerability while also evaluating pharmacokinetics and preliminary efficacy.

Further product details are provided in the report……..

Fragile X Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Fragile X Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Fragile X Syndrome
• There are approx. 12+ key companies which are developing the therapies for Fragile X Syndrome. The companies which have their Fragile X Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Shionogi.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Fragile X Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fragile X Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Fragile X Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fragile X Syndrome drugs.

Fragile X Syndrome Report Insights

• Fragile X Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Fragile X Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Fragile X Syndrome drugs?
• How many Fragile X Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fragile X Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fragile X Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fragile X Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Shionogi
• CONNECTA Therapeutics
• Marvel Biosciences Corp.
• NeuroNascent, Inc.
• Spinogenix
• Servier
• Quiver Bioscience

Key Products

• Zatolmilast
• CTH120
• MB-204
• NNI-351
• SPG601
• S247240
• Research Program